REPROCELL
Karen Bingham began their work experience as a PhD student at the University of Glasgow in 1993 and completed it in 1997. Karen then worked as a Study Director/Manager/Scientist at Q-One Biotech/BioReliance/Invitrogen from 1998 to 2006. From 2006 to 2011, they were the Head of Operations at Biopta Ltd, and from 2011 to 2015, they served as the Global Head of Operations at the same company. Finally, in 2015, Karen became the COO of REPROCELL.
Karen Bingham received a Bachelor of Science (Hons) degree in Molecular Biology from the University of Glasgow, where they studied from 1989 to 1993. Karen then pursued a PhD in Cell Engineering sponsored by Ethicon, a Johnson & Johnson company, from 1993 to 1997 also at the University of Glasgow.
This person is not in any offices
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.